Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027

Loading news article.

Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027 | WAPE

Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027

Article summary

Related companies

Comments —